Atorvastatin strontium
Based on 63 publication(s) in Google Scholar
Strontium atorvastatin is a cholesterol-lowering drug with activity in ameliorating cardiovascular disease-related events. Strontium atorvastatin exerts its biological activity by inhibiting HMG-CoA reductase in liver tissue. Strontium atorvastatin is also used to suppress dyslipidemia.
For research use only. We do not sell to patients.
- CAS No.: 1072903-92-4
- Formula: C33H35FN2O5.1/2Sr
- Molecular Weight:602.06
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Atorvastatin strontium
More- Signal Transduct Target Ther. 2025 Nov 12;10(1):366. [Abstract]
- Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]
- Nat Aging. 2025 Aug 26. [Abstract]
- Nat Neurosci. 2026 Jun;29(6):1369-1385. [Abstract]
- Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. [Abstract]
- MedComm (2020). 2024 Aug 31;5(9):e681. [Abstract]
- Cell Death Differ. 2026 Jul 24.
- Cancer Lett. 2023 Jan 1:552:215976. [Abstract]
- Phytomedicine. 2025 Oct:146:157128. [Abstract]
- Phytomedicine. 2025 Jul:142:156713. [Abstract]
- Phytomedicine. 2023 Jul 26;119:154997. [Abstract]
- Acta Pharmacol Sin. 2024 Jun;45(6):1316-1320. [Abstract]
- Oncogene. 2022 Dec;41(49):5266-5278. [Abstract]
- Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. [Abstract]
- Environ Sci Technol Lett. 2025 Apr 8.
- Emerg Microbes Infect. 2025 Dec;14(1):2470371. [Abstract]
- J Agric Food Chem. 2026 Aug 5;74(30):23481-23494.
- Life Sci. 2025 Jun 1:370:123571. [Abstract]
- Pharmaceuticals (Basel). 2026 Aug 24;19(9):1338.
- Eur J Pharmacol. 2025 Apr 5:992:177357. [Abstract]
- Eur J Pharmacol. 2024 Feb 5:964:176261. [Abstract]
- Eur J Pharmacol. 2023 Oct 5:956:175938. [Abstract]
- Int Immunopharmacol. 2026 Apr 1:174:116346. [Abstract]
- Int Immunopharmacol. 2025 Dec 3:166:115644. [Abstract]
- Int J Mol Sci. 2023 Apr 19;24(8):7492. [Abstract]
- Front Pharmacol. 2025 Apr 30:16:1573032. [Abstract]
- Inflammation. 2024 Oct 31. [Abstract]
- Front Cell Dev Biol. 2022 Mar 3;10:806081. [Abstract]
- Chem Biol Interact. 2025 Oct 22:420:111671. [Abstract]
- Bioorg Chem. 2026 Jul 23:181:110282.
- Clin Pharmacol Ther. 2025 Jul 14. [Abstract]
- Sci Rep. 2020 Jan 28;10(1):1308. [Abstract]
- Exp Neurol. 2025 Sep:391:115305. [Abstract]
- Nanomedicine (Lond). 2026 Mar;21(6):789-801. [Abstract]
- Ann N Y Acad Sci. 2026 Mar;1557(1):e70224. [Abstract]
- FASEB J. 2026 May 15;40(9):e71873. [Abstract]
- Med Gas Res. 2025 Mar 1;15(1):148-155. [Abstract]
- J Virol. 2026 Jun 9:e0030126. [Abstract]
- Proteomics. 2023 Aug;23(16):e2300041. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3659-3670. [Abstract]
- J Tradit Complement Med. 2024 Mar 29;14(6):656-665. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- Cell Cycle. 2021 Oct;20(20):2160-2173. [Abstract]
- Cell Cycle. 2019 Dec;18(23):3337-3350. [Abstract]
- Endocrinology. 2022 Jul 1;163(7):bqac076. [Abstract]
- J Nat Prod. 2022 Jul 22;85(7):1738-1750. [Abstract]
- Exp Cell Res. 2023 Dec 15;433(2):113829. [Abstract]
- Acta Diabetol. 2025 Mar 27. [Abstract]
- J Appl Toxicol. 2024 Aug;44(8):1198-1213. [Abstract]
- J Neuroimmunol. 2021 Jan 15:350:577429. [Abstract]
- FEBS Open Bio. 2025 Aug 8. [Abstract]
- J Mol Neurosci. 2022 Mar;72(3):565-573. [Abstract]
- Oncologie. 2025 May 26.
- Biomed Pharmacother. 2026 Sep:202:119803.
- University of Central Florida. 2026.
- SSRN. 2026 May 20.
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Apr 9.
- Orebro University. 2024.
- Research Square Preprint. 2024 Apr 9.
- Biomed Pharmacother. 2023 Oct:166:115323. [Abstract]
- Research Square Preprint. 2022 Jun.
- Research Square Preprint. 2021 Dec.
-
In Vivo Efficacy Study
-
WB
-
WB
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
Description
Chemical Information
-
CAS No. 1072903-92-4
-
Molecular Weight 602.06
-
Formula C33H35FN2O5.1/2Sr
-
SMILES
O=C(C1=C(C(C)C)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C2=CC=C(C=C2)F)=C1C3=CC=CC=C3)NC4=CC=CC=C4.[1/2Sr]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (63)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2025 Nov 12;10(1):366. PMID: 41219186 -
Signal Transduct Target Ther
2023 Dec 25;8(1):457. PMID: 38143263
Atorvastatin strontium purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]
EGFRvIII-high U87 cells were cocultured with EGFRvIII-CAR-T cells and treated with Atorvastatin (5 μM, 3 days) or Cytochalasin D (10 μg/mL, 1 day). Immunoblotting of magnetically separated cells showed that both drugs alleviated CAR molecule transfer (representative of three independent experiments).
-
Nat Aging
2025 Aug 26. PMID: 40858817 -
Nat Neurosci
Amyloid-β-driven glymphatic dysfunction in Alzheimer's disease model mice is driven by Ca2+-mediated increases in astrocytic cholesterol. [Abstract]2026 Jun;29(6):1369-1385. PMID: 41986732 -
Mol Cell
The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. [Abstract]2021 Jul 1;81(13):2736-2751.e8. PMID: 33932349
Atorvastatin strontium purchased from MedChemExpress. Usage Cited in: Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. [Abstract]
Tumor volumes of indicated patient-derived xenografts (PDXs) treated with Atorvastatin (40 mg/kg, i.p., every two days for 30 days).
-
MedComm (2020)
Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [Abstract]2024 Aug 31;5(9):e681. PMID: 39220103 -
-
Cancer Lett
Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. [Abstract]2023 Jan 1:552:215976. PMID: 36272615
Atorvastatin strontium purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Jan 1:552:215976. [Abstract]
Panc-1 and MIA PaCa-2 cells were treated with Atorvastatin (20 μM or 50 μM) for 24 h. FOXM1 and mutant p53 protein levels were measured in different treatment groups.
-
Phytomedicine
Mori fructus-derived extracellular vesicle-like nanoparticles regulate dyslipidemia and prevent atherosclerosis progression via miRNAs. [Abstract]2025 Oct:146:157128. PMID: 40815949
Atorvastatin strontium purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157128. [Abstract]
ApoE-/- mice were administrated with high-fat-diet accompanied by MFEVLPs (5 or 50 μg/d, i.p) or Atorvastatin (10 mg/kg/day, i.g) for 12 weeks.
-
Phytomedicine
Bioactive equivalent combinatorial components of Xiao-Xu-Ming decoction inhibit the calmodulin-mediated MLCK/MLC axis to attenuate coronary artery spasm. [Abstract]2025 Jul:142:156713. PMID: 40349422 -
Phytomedicine
Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade. [Abstract]2023 Jul 26;119:154997. PMID: 37523836 -
Acta Pharmacol Sin
2024 Jun;45(6):1316-1320. PMID: 38459255 -
Oncogene
Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc. [Abstract]2022 Dec;41(49):5266-5278. PMID: 36316442
Atorvastatin strontium purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Dec;41(49):5266-5278. [Abstract]
ATP assay. The combination of Atorvastatin (2.5, 5, 10, 20 μM; 48 h) and SR1078 synergistically inhibits CRC cell viability.
-
Arterioscler Thromb Vasc Biol
N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. [Abstract]2022 May;42(5):644-658. PMID: 35296150 -
Atorvastatin strontium purchased from MedChemExpress. Usage Cited in: Environ Sci Technol Lett. 2025 Apr 8.
The hCMEC-D3 cells were exposed to 0.01 μM 77PD-Q for 24 h in the presence or absence of 0.3 μM Atorvastatin (0.3 μM, 24 h).
-
Emerg Microbes Infect
SREBP2-dependent lipid droplet formation enhances viral replication and deteriorates lung injury in mice following IAV infection. [Abstract]2025 Dec;14(1):2470371. PMID: 39968754 -
-
Life Sci
CKN reduces TLR4-mediated inflammation and cerebral I/R injury by activating the LXRα/ABCA1 pathway in microglia. [Abstract]2025 Jun 1:370:123571. PMID: 40107493 -
-
Eur J Pharmacol
Protective effects of atorvastatin on testicular dysfunction and reduced sperm quality induced by high-fat diet in mice: The inhibitory mechanism of oxidative stress. [Abstract]2025 Apr 5:992:177357. PMID: 39921059 -
Eur J Pharmacol
Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis. [Abstract]2024 Feb 5:964:176261. PMID: 38141938 -
Eur J Pharmacol
DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE-/- mice via suppressing inflammation, endothelial necroptosis and apoptosis. [Abstract]2023 Oct 5:956:175938. PMID: 37536623 -
Int Immunopharmacol
Milk exosomes loaded with atorvastatin suppress fibroblast activation and extracellular matrix remodeling via the TGF-β/SMAD pathway in ligamentum flavum hypertrophy. [Abstract]2026 Apr 1:174:116346. PMID: 41707594 -
Int Immunopharmacol
Structural polysaccharide PCP1 from Polygonatum cyrtonema Hua attenuates atherosclerosis via dual-target suppression of CD36/MSR1 and TLR4/NF-κB pathways. [Abstract]2025 Dec 3:166:115644. PMID: 41045802 -
Int J Mol Sci
Effects of Dietary Cholesterol Regulation on Spermatogenesis of Gobiocypris rarus Rare Minnow. [Abstract]2023 Apr 19;24(8):7492. PMID: 37108655 -
Front Pharmacol
Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells. [Abstract]2025 Apr 30:16:1573032. PMID: 40371351 -
Inflammation
2024 Oct 31. PMID: 39480573 -
Front Cell Dev Biol
Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]2022 Mar 3;10:806081. PMID: 35309902 -
Chem Biol Interact
Subchronic exposure to CeCl3 promotes macrophage ferroptosis and atherosclerotic plaque formation by inhibiting the Keap1/Nrf2/GPX4 pathway. [Abstract]2025 Oct 22:420:111671. PMID: 40706741 -
-
Clin Pharmacol Ther
Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™). [Abstract]2025 Jul 14. PMID: 40657937 -
Sci Rep
Scutellarin inhibition of the rosuvastatin uptake in rat hepatocytes and the competition for organic anion transporting polypeptide 1B1 in HEK293T cells. [Abstract]2020 Jan 28;10(1):1308. PMID: 31992796 -
Exp Neurol
Salvianolic acid B exerts cerebroprotective effects after traumatic brain injury via Nrf2-dependent antioxidant and anti-inflammatory cascades. [Abstract]2025 Sep:391:115305. PMID: 40383364 -
Nanomedicine (Lond)
Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction. [Abstract]2026 Mar;21(6):789-801. PMID: 41660754 -
Ann N Y Acad Sci
The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. [Abstract]2026 Mar;1557(1):e70224. PMID: 41774091 -
FASEB J
Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]2026 May 15;40(9):e71873. PMID: 42087353 -
Med Gas Res
The augment effects of magnesium hydride on the lipid lowering effect of atorvastatin: an in vivo and in vitro investigation. [Abstract]2025 Mar 1;15(1):148-155. PMID: 39436189 -
J Virol
The cholesterol transporter Niemann-Pick C1 facilitates the entry of porcine epidemic diarrhea coronavirus. [Abstract]2026 Jun 9:e0030126. PMID: 42262129 -
Proteomics
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]2023 Aug;23(16):e2300041. PMID: 37140101 -
Naunyn Schmiedebergs Arch Pharmacol
Bisdemethoxycurcumin suppresses the progression of atherosclerosis and VSMC-derived foam cell formation by promoting lipophagy. [Abstract]2023 Dec;396(12):3659-3670. PMID: 37289282 -
J Tradit Complement Med
Zhilong Huoxue Tongyu capsule protects against atherosclerosis by suppressing EndMT via modulating Hippo/YAP signaling pathway. [Abstract]2024 Mar 29;14(6):656-665. PMID: 39850597 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Cell Cycle
Atorvastatin inhibited TNF-α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-κB signaling. [Abstract]2021 Oct;20(20):2160-2173. PMID: 34494933 -
Cell Cycle
Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. [Abstract]2019 Dec;18(23):3337-3350. PMID: 31599189 -
Endocrinology
2022 Jul 1;163(7):bqac076. PMID: 35583599 -
J Nat Prod
Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway. [Abstract]2022 Jul 22;85(7):1738-1750. PMID: 35749236 -
Exp Cell Res
Rapamycin promotes hematoma resorption and enhances endothelial cell function by suppressing the mTOR/STAT3 signaling in chronic subdural hematoma. [Abstract]2023 Dec 15;433(2):113829. PMID: 37879548 -
Acta Diabetol
Identification of FLVCR1 as the iron metabolism-related gene of statin-associated diabetes. [Abstract]2025 Mar 27. PMID: 40146399 -
J Appl Toxicol
2024 Aug;44(8):1198-1213. PMID: 38639436 -
J Neuroimmunol
The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. [Abstract]2021 Jan 15:350:577429. PMID: 33176238 -
FEBS Open Bio
Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]2025 Aug 8. PMID: 40781787 -
J Mol Neurosci
Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages. [Abstract]2022 Mar;72(3):565-573. PMID: 34569007 -
-
-
-
-
-
-
-
-
Biomed Pharmacother
2023 Oct:166:115323. PMID: 37579692 -
-
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
[1]. Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22. [Content Brief]
[2]. Systemic drugs with impact on osteoarthritis [Content Brief]
[3]. Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61. [Content Brief]
[4]. Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82. [Content Brief]
[5]. Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72. [Content Brief]
[6]. Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821. [Content Brief]
[7]. Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)